Resumen

ROSSELLI, Diego; DIAZ, Carlos Eduardo  y  GUTIERREZ, Laura. Clinical outcomes in Hemato-Oncology: Ten year Pubmed literature review. rev.colomb.cancerol. [online]. 2015, vol.19, n.2, pp.95-102. ISSN 0123-9015.  https://doi.org/10.10167j.rccan.2015.02.002.

Objective: To describe the clinical outcomes used in phase III studies in Hematology-Oncology malignancies, and to determine what proportion use overall survival as the primary outcome. Methods: Using a systematic literature search in PubMed, an analysis was made of phaseIII randomized clinical trials with de novo treatments of hematology-oncological neoplasias in adult populations published in the last 10 years. Results: The initial search yielded 310 references, 90 of which were finally selected. The overall survival rate was used in 20 studies (22%) as the primary outcome (in 3 of them it reached statistical significance). Grouped intermediate outcomes were used in 37 others (41%). As a secondary outcome the overall survival rate was used in 55 studies (61%). Among the intermediate outcomes used were, response rates, disease-free or relapse-free survival rates, and progression-free survival rate. Multiple myeloma was the most studied disease, with 29 studies (32%), followed by non-Hodgkin lymphoma (28%). Conclusions: Although overall survival rate is the gold standard in cancer therapy, it is not the most often used outcome. Intermediate outcomes, such as disease-free survival or biomarkers are often good predictors, and require smaller samples and less follow-up time. Nevertheless, their predictive capacity for overall survival rate (or, in some cases, quality of life) should also be assessed. The use of the overall survival rate as the routine primary outcome is only justified in the most aggressive forms of cancer.

Palabras clave : Multiple myeloma; Leukemia; Lymphoma; Randomized controlled trial; Medical oncology; Intermediate endpoints; Survival Rate.

        · resumen en Español     · texto en Español     · Español ( pdf )